There was an increasing trend of multiagent therapies over time, with 155 (40.1%), 168 (50.0%), and 156 (50.2%), respectively per era, who received multiagent chemotherapy.
← all excerpts
Long term outcomes of older patients with classical hodgkin lymphoma: an analysis of the Texas cancer registry.
1
—
—